Baricitinib versus Tocilizumab in Critically Ill COVID ‐19 Patients: A Retrospective Cohort Study
ConclusionsBaricitinib use was associated with better WHO-CPS scores at day 14 and day 7 compared with tocilizumab in a cohort of critically ill patients with COVID-19. The odds of having a one unit increase in WHO-CPS score at day 14 was 71% higher with tocilizumab than baricitinib. No difference in mortality or adverse effects was noted.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - Category: Drugs & Pharmacology Authors: Grace M. Conroy,
Seth R. Bauer,
Andrea M. Pallotta,
Abhijit Duggal,
Lu Wang,
Gretchen L. Sacha Tags: RESEARCH ARTICLE Source Type: research
More News: Actemra | Coronavirus | COVID-19 | Dexamethasone | Drugs & Pharmacology | International Medicine & Public Health | Study | WHO